| Tara Lynn Thurston, DO | |
|
228 Billerica Rd, Chelmsford, MA 01824-3604 | |
| (978) 250-6300 | |
| (978) 250-6335 |
| Full Name | Tara Lynn Thurston |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 228 Billerica Rd, Chelmsford, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790830495 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 231592 (Massachusetts) | Primary |
| Entity Name | Reliant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720017528 PECOS PAC ID: 5597755322 Enrollment ID: O20040708000650 |
News Archive
A survey of older rural adults found a high degree of medical skepticism, the belief that one knows and can control their own health better than a medical professional can, reports a recent study in the Journal of Health Care for the Poor and Underserved. For some, these beliefs correlate with a higher tendency toward self-care.
With the recent completion of its latest treatment campaign against intestinal parasites, Cambodia has become the first country to protect three out of four school-aged children against intestinal parasites and reach WHO's anti-parasite target – six years ahead of schedule.
AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tara Lynn Thurston, DO 228 Billerica Rd, Chelmsford, MA 01824-3604 Ph: (978) 250-6300 | Tara Lynn Thurston, DO 228 Billerica Rd, Chelmsford, MA 01824-3604 Ph: (978) 250-6300 |
News Archive
A survey of older rural adults found a high degree of medical skepticism, the belief that one knows and can control their own health better than a medical professional can, reports a recent study in the Journal of Health Care for the Poor and Underserved. For some, these beliefs correlate with a higher tendency toward self-care.
With the recent completion of its latest treatment campaign against intestinal parasites, Cambodia has become the first country to protect three out of four school-aged children against intestinal parasites and reach WHO's anti-parasite target – six years ahead of schedule.
AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.
› Verified 5 days ago
Chandra Ramanathan, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 228 Billerica Rd, Chelmsford, MA 01824 Phone: 978-250-6000 | |
Dr. Mark Gordon Gilchrist, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4 Meeting House Rd, Chelmsford, MA 01824 Phone: 978-250-4081 Fax: 978-250-3956 | |
Sheila L Morehouse, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7 Village Sq, Chelmsford, MA 01824 Phone: 978-256-4363 | |
Jennifer Marie Liano, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 228 Billerica Rd, Chelmsford, MA 01824 Phone: 978-250-6300 | |
Francheyska Silfa Mazara, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3 Kirby Ln, Chelmsford, MA 01824 Phone: 617-650-1685 | |
Dr. Lorna Shaw Melo, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 228 Billerica Rd, Pediatrics Dept, Chelmsford, MA 01824 Phone: 978-250-6300 | |
Beril Bayrak, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 7 Village Sq, Chelmsford, MA 01824 Phone: 978-256-4363 Fax: 978-256-1565 |